Atrial fibrillation (AF) is a common heart rhythm disorder that increases the risk of stroke and other heart-related complications. Anticoagulation therapy is essential for managing patients with ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

There is decreased risk for MACE, stroke, and mortality in patients with newly diagnosed atrial fibrillation who regularly use statins.

That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only ...

Promising results show that abelacimab could revolutionize anticoagulation therapy by slashing bleeding risks without compromising stroke protection for patients with atrial fibrillation.

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue ...

Recent research shows the incredible success of radiofrequency ablation in treating AFib, offering renewed hope for patients.

Background Atrial fibrillation (AF) and acute myocardial infarction (AMI) share risk factors and are bidirectionally associated. Several studies found higher risks of outcomes in individuals with both ...

Countries such as China and India are expected to lead the market. The ageing population and the increasing prevalence of ...